کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
4128232 | 1270915 | 2013 | 14 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Mise en place d'un secteur de pathologie moléculaire en oncologie au sein d'un laboratoire d'anatomie pathologique (LPCE, CHU de Nice)
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
ISO 15189molecular pathology - آسیب شناسی مولکولیPathologie moléculaire - آسیب شناسی مولکولیAccreditation - اعتباربخشیAssurance qualité - تضمین کیفیتQuality assurance - تضمین کیفیت، QATargeted therapy - درمان هدفمندThérapie ciblée - درمان هدفمندBiologie moléculaire - زیست شناسی مولکولیMolecular biology - زیستشناسی مولکولی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
آسیبشناسی و فناوری پزشکی
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Mise en place d'un secteur de pathologie moléculaire en oncologie au sein d'un laboratoire d'anatomie pathologique (LPCE, CHU de Nice) Mise en place d'un secteur de pathologie moléculaire en oncologie au sein d'un laboratoire d'anatomie pathologique (LPCE, CHU de Nice)](/preview/png/4128232.png)
چکیده انگلیسی
The advent of targeted therapies and personalized medicine in oncology has led in France to the settlement and organisation of a network of hospital molecular genetic platforms under the impetus of the National Cancer Institute (INCa). These platforms are, according to the concerned sites, integrated or not in pathology laboratories. The development of molecular biology methods, the choice of the procedures, the establishment of sample workflow, the quality control and the selection of the genomic alterations to be detected on each platform, have been left to the discretion of the different laboratories. Based on calls for project made by the INCa, hospital molecular genetic platforms were able to adapt their activity according to the assigned budgets. While the presence of some genomic alterations (i.e. KRAS gene mutations in metastatic colon adenocarcinoma or EGFR gene mutations in lung adenocarcinomas), may lead to administration of targeted therapies under the Marketing Authorization Application (MAA), others are associated with therapeutic clinical trials. However, increasing number of MAA for new molecules targeting genomic alterations is likely in the near future. In this context, it is necessary to quickly adapt the organisation of work of the hospital pathology laboratories performing molecular biology tests in order to meet the growing demand of oncologists in the field of targeted therapies. The purpose of this article is to describe the different steps of the settlement of a molecular genetic platform in an academic pathology laboratory (LPCE, CHU de Nice) and to show the experience of this laboratory specifically oriented on the support of the morphological and molecular diagnosis of lung cancer, thyroid cancer and malignant melanoma.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Annales de Pathologie - Volume 33, Issue 1, February 2013, Pages 24-37
Journal: Annales de Pathologie - Volume 33, Issue 1, February 2013, Pages 24-37
نویسندگان
Elodie Long, Véronique Hofman, Marius Ilie, Virgine Lespinet, Christelle Bonnetaud, Olivier Bordone, Virginie Gavric-Tanga, Kevin Washetine, Marie-Clotilde Gaziello, Virginie Mauro, Sandra Lassalle, Eric Selva, Katia Zahaf, José Santini,